| Literature DB >> 35170223 |
Arun K Ghosh1, Satish Kovela1, Ashish Sharma1, Dana Shahabi1, Ajay K Ghosh1, Denver R Hopkins1, Monika Yadav1, Megan E Johnson1, Johnson Agniswamy2, Yuan-Fang Wang2, Shin-Ichiro Hattori3, Nobuyo Higashi-Kuwata3, Manabu Aoki4, Masayuki Amano4, Irene T Weber2, Hiroaki Mitsuya4,5,6,7.
Abstract
The design, synthesis, X-ray structural, and biological evaluation of a series of highly potent HIV-1 protease inhibitors are reported herein. These inhibitors incorporate novel cyclohexane-fused tricyclic bis-tetrahydrofuran as P2 ligands in combination with a variety of P1 and P2' ligands. The inhibitor with a difluoromethylphenyl P1 ligand and a cyclopropylaminobenzothiazole P2' ligand exhibited the most potent antiviral activity. Also, it maintained potent antiviral activity against a panel of highly multidrug-resistant HIV-1 variants. The corresponding inhibitor with an enantiomeric ligand was significantly less potent in these antiviral assays. The new P2 ligands were synthesized in optically active form using enzymatic desymmetrization of meso-diols as the key step. To obtain molecular insight, two high-resolution X-ray structures of inhibitor-bound HIV-1 protease were determined and structural analyses have been highlighted.Entities:
Keywords: HIV-1 protease; antiviral agents; backbone binding; inhibitors; multidrug-resistance
Mesh:
Substances:
Year: 2022 PMID: 35170223 PMCID: PMC9081228 DOI: 10.1002/cmdc.202200058
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.540